The increased expression of PD-L1 by tumor cells may make them susceptible to antibody-dependent cell-mediated cytotoxicity (ADCC) by human immune effector cells when stimulated by an IgG1 subclass antibody that has an active Fc region, such as avelumab [49]. Here, CD274 is linked to neoplasm.